reports
Kingsway Financial Services Inc: 1 director
A director at Kingsway Financial Services Inc sold 68,000 shares at 14.449USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Carpenter Technology Announces GICS Aerospace & Defense Sector Reclass...
Carpenter Technology Announces GICS Aerospace & Defense Sector Reclassification PHILADELPHIA, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) today confirmed that its Global Industry Classification Standard (GICS) designation, as determined by MSCI Inc. and S&P Dow Jones Indices, has been reclassified to 20101010 – Aerospace & Defense, effective September 30, 2025. “While we remain focused on the execution of our strategy to drive long-term value, we believe this update will enhance our visibility with sector-focused investors and support a valuation that ...
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® ...
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of M...
Amicus Therapeutics to Present at Upcoming Investor Conferences in Sep...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET A live audio webcast of each presentation can also be accessed via ...
Carpenter Technology Corp: 2 directors
Two Directors at Carpenter Technology Corp sold after exercising options/sold 24,691 shares at between 244.545USD and 244.992USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...
Carpenter Technology Declares Quarterly Cash Dividend
Carpenter Technology Declares Quarterly Cash Dividend PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share of common stock, payable September 4, 2025, to shareholders of record on August 26, 2025. About Carpenter Technology Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, and other markets. Founded in 1889, Carpente...
Carpenter Technology’s Board of Directors Elects Tony Thene as Chairma...
Carpenter Technology’s Board of Directors Elects Tony Thene as Chairman and CEO PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced the execution of succession plans for the Board of Directors. Carpenter Technology’s Board of Directors has unanimously elected Tony R. Thene, current President and Chief Executive Officer, to assume the additional duties of Chairman of the Board, effective October 7, 2025, immediately before the commencement of the 2025 Annual Stockholders Meeting. For the last 10 years, Mr. Thene ha...
Carpenter Technology Reports Fourth Quarter and Fiscal Year 2025 Resul...
Carpenter Technology Reports Fourth Quarter and Fiscal Year 2025 Results Delivered Record Quarterly Operating Income in Fourth Quarter Generated Record Adjusted Free Cash Flow in Fourth Quarter Completed Most Profitable Year in Company History Fiscal Year 2026 Outlook 26% to 33% Higher Than Record Fiscal Year 2025 PHILADELPHIA, July 31, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal fourth quarter and year ended June 30, 2025. For the quarter, the Company reported operating income of $151.4 million...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results an...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, tod...
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results ...
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event...
Carpenter Technology Announces Conference Call and Webcast
Carpenter Technology Announces Conference Call and Webcast PHILADELPHIA, July 07, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 31, 2025 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2025, ended June 30, 2025. The call and webcast will follow the release of fourth quarter fiscal 2025 financial results before the market opens on Thursday, July 31, 2025. Conference Call and Webcast Details What: Carpenter Technology Fourth Quarter Fiscal 2025 Conference Call...
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase ...
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (mig...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in Jun...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors sectio...
Amicus Therapeutics to Present at the Bank of America 2025 Health Care...
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at . About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology ...
Amicus Therapeutics Announces First Quarter 2025 Financial Results and...
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates 1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and We...
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement f...
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-ba...
Carpenter Technology Reports Third Quarter Fiscal Year 2025 Results
Carpenter Technology Reports Third Quarter Fiscal Year 2025 Results Delivered Most Profitable Quarter in Company HistoryExceeded Third Quarter Operating Income GuidanceExpanded Operating Margins in Specialty Alloys Operations SegmentGenerated Positive Adjusted Free Cash FlowRepurchased Shares Against Authorized Share Repurchase ProgramRaising Fiscal Year 2025 Guidance PHILADELPHIA, April 24, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2025. For the quarter, ...
Amicus Therapeutics to Announce First Quarter 2025 Financial Results o...
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A ...
Carpenter Technology Declares Quarterly Cash Dividend
Carpenter Technology Declares Quarterly Cash Dividend PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share of common stock, payable June 5, 2025, to shareholders of record on April 22, 2025. About Carpenter Technology Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, and other markets. Founded in 1889, Carpenter Tec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.